LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 430

Search options

  1. Article ; Online: Artificial Intelligence and the potential for Garbage In, Garbage Out.

    Citrome, Leslie

    Current medical research and opinion

    2024  Volume 40, Issue 1, Page(s) 1–2

    MeSH term(s) Humans ; Artificial Intelligence ; Garbage
    Language English
    Publishing date 2024-01-03
    Publishing country England
    Document type Editorial
    ZDB-ID 80296-7
    ISSN 1473-4877 ; 0300-7995
    ISSN (online) 1473-4877
    ISSN 0300-7995
    DOI 10.1080/03007995.2023.2286785
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Vive la révolution! a paradigm shift in the pharmacological treatment of schizophrenia.

    Citrome, Leslie

    Current medical research and opinion

    2023  Volume 39, Issue 3, Page(s) 473–474

    MeSH term(s) Humans ; Schizophrenia/drug therapy
    Language English
    Publishing date 2023-01-27
    Publishing country England
    Document type Editorial
    ZDB-ID 80296-7
    ISSN 1473-4877 ; 0300-7995
    ISSN (online) 1473-4877
    ISSN 0300-7995
    DOI 10.1080/03007995.2023.2168955
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Number needed to treat and number needed to harm: What are they good for?

    Citrome, Leslie

    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

    2023  Volume 68, Page(s) 105–107

    MeSH term(s) Risk Assessment ; Numbers Needed To Treat
    Language English
    Publishing date 2023-01-27
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1082947-7
    ISSN 1873-7862 ; 0924-977X
    ISSN (online) 1873-7862
    ISSN 0924-977X
    DOI 10.1016/j.euroneuro.2022.12.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Editor-in-Chief Foreword: can we engage in evidence-based medicine by using practice-based evidence?

    Citrome, Leslie

    Current medical research and opinion

    2023  Volume 39, Issue 12, Page(s) 1535–1536

    MeSH term(s) Humans ; Evidence-Based Medicine
    Language English
    Publishing date 2023-12-15
    Publishing country England
    Document type Editorial
    ZDB-ID 80296-7
    ISSN 1473-4877 ; 0300-7995
    ISSN (online) 1473-4877
    ISSN 0300-7995
    DOI 10.1080/03007995.2023.2287865
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Book: Handbook of treatment resistant schizophrenia

    Citrome, Leslie

    2013  

    Title variant Handbook of treatment-resistant schizophrenia
    Author's details Leslie Citrome
    Language English
    Size X, 66 S.
    Publisher Springer Healthcare
    Publishing place London
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT018137539
    ISBN 978-1-908517-86-9 ; 1-908517-86-7
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  6. Article: Long-acting injectable antipsychotics: what, when, and how - Addendum.

    Citrome, Leslie

    CNS spectrums

    2021  Volume 26, Issue 2, Page(s) 184

    Language English
    Publishing date 2021-04-29
    Publishing country United States
    Document type Journal Article ; Published Erratum
    ZDB-ID 2008418-3
    ISSN 2165-6509 ; 1092-8529
    ISSN (online) 2165-6509
    ISSN 1092-8529
    DOI 10.1017/S1092852921000456
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Long-acting injectable antipsychotics: what, when, and how - CORRIGENDUM.

    Citrome, Leslie

    CNS spectrums

    2021  Volume 27, Issue 6, Page(s) 764

    MeSH term(s) Humans ; Antipsychotic Agents/therapeutic use ; Schizophrenia/drug therapy ; Delayed-Action Preparations/therapeutic use
    Chemical Substances Antipsychotic Agents ; Delayed-Action Preparations
    Language English
    Publishing date 2021-09-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2008418-3
    ISSN 2165-6509 ; 1092-8529
    ISSN (online) 2165-6509
    ISSN 1092-8529
    DOI 10.1017/S1092852921000778
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder.

    Faden, Justin / Citrome, Leslie

    Schizophrenia research

    2024  

    Abstract: Although uncommon, the risk of aggression and violence is greater in people with schizophrenia than in the general population. Clozapine is the "gold standard" pharmacologic treatment for the management of persistent agitation and aggression in people ... ...

    Abstract Although uncommon, the risk of aggression and violence is greater in people with schizophrenia than in the general population. Clozapine is the "gold standard" pharmacologic treatment for the management of persistent agitation and aggression in people with schizophrenia and is consistently recommended by guidelines and reviews for this purpose. Although clozapine is indicated for treatment-resistant schizophrenia based on its superior efficacy, studies have proposed that clozapine may have specific properties that ameliorate aggression and hostility that are distinct from its antipsychotic effects. A literature review was conducted on June 3, 2023, using the US National Library of Medicine's PubMed resource to identify articles focusing on clozapine for the treatment of aggression, violence, and/or hostility in patients with schizophrenia or schizoaffective disorder. The majority of evidence, including from randomized control trials, supports the utilization of clozapine as maintenance treatment for persistent aggressive behavior in patients with schizophrenia, and supports that its anti-aggressive effects may be independent from its antipsychotic properties (e.g. - treatment of hallucinations and delusions). Future randomized control studies evaluating clozapine and clozapine serum levels with aggression as the primary outcome would be of benefit.
    Language English
    Publishing date 2024-01-29
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 639422-x
    ISSN 1573-2509 ; 0920-9964
    ISSN (online) 1573-2509
    ISSN 0920-9964
    DOI 10.1016/j.schres.2023.11.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia.

    Ward, Kristen / Citrome, Leslie

    Expert opinion on drug safety

    2024  Volume 23, Issue 4, Page(s) 399–409

    Abstract: Introduction: Antipsychotics are the foundation of pharmacologic treatment for schizophrenia. There are many oral antipsychotics available and given that these medications are generally considered comparably efficacious when titrated to an adequate dose, ...

    Abstract Introduction: Antipsychotics are the foundation of pharmacologic treatment for schizophrenia. There are many oral antipsychotics available and given that these medications are generally considered comparably efficacious when titrated to an adequate dose, their varied tolerability, and safety profiles become critically important for medication selection.
    Areas covered: This paper reviews tolerability and safety considerations for first-line second-generation oral antipsychotics currently approved for the treatment of schizophrenia in the USA. Excluded from consideration are clozapine and non-oral formulations.
    Expert opinion: Among antipsychotics, there are many differences in adverse reactions observed in clinical trials, such as variable likelihood to cause sedation vs insomnia, weight gain and abnormalities in glucose/lipid metabolism, hyperprolactinemia, potential for impact on the QT interval, and motoric adverse effects. Additional safety data that can help with medication selection include safety in pregnancy and lactation, and potential for drug-drug interactions. Ultimately, working with patients to personalize treatment by focusing on safety and individual tolerability considerations for various adverse effects can help in building a therapeutic alliance and improving patients' outcomes.
    MeSH term(s) Humans ; Antipsychotic Agents/adverse effects ; Schizophrenia/drug therapy ; Clozapine/therapeutic use ; Hyperprolactinemia/chemically induced ; Thiazoles/therapeutic use
    Chemical Substances Antipsychotic Agents ; Clozapine (J60AR2IKIC) ; Thiazoles
    Language English
    Publishing date 2024-03-25
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2088728-0
    ISSN 1744-764X ; 1474-0338
    ISSN (online) 1744-764X
    ISSN 1474-0338
    DOI 10.1080/14740338.2024.2328812
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Agitation in schizophrenia: origins and evidence-based treatment.

    Citrome, Leslie

    Current opinion in psychiatry

    2021  Volume 34, Issue 3, Page(s) 216–221

    Abstract: Purpose of review: Agitation associated with schizophrenia remains an important clinical concern and if not managed effectively, can escalate into aggressive behavior. This is a review of the recent biomedical literature on agitation in individuals with ...

    Abstract Purpose of review: Agitation associated with schizophrenia remains an important clinical concern and if not managed effectively, can escalate into aggressive behavior. This is a review of the recent biomedical literature on agitation in individuals with schizophrenia.
    Recent findings: Themes in the recent literature include consideration of comorbidities such as cigarette smoking and cannabis use. Surveys reveal that pharmacological approaches to manage agitation have changed little, with haloperidol remaining in common use and intramuscular administration of antipsychotics and/or benzodiazepines being frequently administered to more severely agitated/aggressive individuals. Of note, ketamine has been recently adopted for use in severe agitation in medical emergency departments, but the risk of this medication for people with schizophrenia is unclear. At present, inhaled loxapine remains the only rapidly acting noninjectable FDA-approved treatment for agitation associated with schizophrenia. In development is an intranasal formulation for olanzapine (a well characterized atypical antipsychotic already approved to treat agitation) and a sublingual film for dexmedetomidine (an α2-adrenergic agonist used as an anesthetic and now being repurposed).
    Summary: Comorbidities can contribute to agitation and can make an accurate differential diagnosis challenging. The ongoing development of rapidly acting novel formulations of antiagitation medications, if successful, may facilitate clinical treatment by providing additional options.
    MeSH term(s) Aggression ; Antipsychotic Agents/therapeutic use ; Benzodiazepines/therapeutic use ; Evidence-Based Medicine ; Humans ; Loxapine/therapeutic use ; Psychomotor Agitation/drug therapy ; Psychomotor Agitation/etiology ; Schizophrenia/complications ; Schizophrenia/drug therapy
    Chemical Substances Antipsychotic Agents ; Benzodiazepines (12794-10-4) ; Loxapine (LER583670J)
    Language English
    Publishing date 2021-01-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 645162-7
    ISSN 1473-6578 ; 0951-7367
    ISSN (online) 1473-6578
    ISSN 0951-7367
    DOI 10.1097/YCO.0000000000000685
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top